Sepsis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Sepsis – Pipeline Review, H2 2017’, provides an overview of the Sepsis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Sepsis

The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects

The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sepsis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sepsis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adrenomed AG

Am-Pharma BV

Arch Biopartners Inc

Aridis Pharmaceuticals LLC

Asahi Kasei Pharma Corp

Aurigene Discovery Technologies Ltd

Batu Biologics Inc

Biomedica Management Corp

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cell2B Advanced Therapeutics SA

Chiome Bioscience Inc

Cilian AG

Commence Bio Inc

DoNatur GmbH

Dr. Franz Kohler Chemie GmbH

Endacea Inc

Evec Inc

Ferring International Center SA

Huons Co Ltd

Immune Response BioPharma Inc

Immunwork Inc

InflaRx GmbH

Integrated BioTherapeutics Inc

Lead Discovery Center GmbH

Leading BioSciences Inc

Lixte Biotechnology Holdings Inc

Merck & Co Inc

Mochida Pharmaceutical Co Ltd

Navigen Inc

Nohla Therapeutics Inc

Novartis AG

Octapharma AG

OncoImmune Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Peptinov SAS

ProThera Biologics Inc

Ra Pharmaceuticals Inc

Recce Ltd

Ribomic Inc

SciClone Pharmaceuticals Inc

SetLance srl

Shionogi & Co Ltd

Sirtex Medical Ltd

SK Biopharmaceuticals Co Ltd

Spider Biotech

Syntiron LLC

Takeda Pharmaceutical Company Ltd

Therakind Ltd

Therashock LLC

TiGenix NV

Vascular BioSciences

ViiV Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Sepsis - Overview 6

Sepsis - Therapeutics Development 7

Sepsis - Therapeutics Assessment 25

Sepsis - Companies Involved in Therapeutics Development 37

Sepsis - Drug Profiles 64

Sepsis - Dormant Projects 267

Sepsis - Discontinued Products 272

Sepsis - Product Development Milestones 274

Appendix 284

List of Tables

List of Tables

Number of Products under Development for Sepsis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Sepsis – Pipeline by Adrenomed AG, H2 2017

Sepsis – Pipeline by Am-Pharma BV, H2 2017

Sepsis – Pipeline by Arch Biopartners Inc, H2 2017

Sepsis – Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Sepsis – Pipeline by Asahi Kasei Pharma Corp, H2 2017

Sepsis – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Sepsis – Pipeline by Batu Biologics Inc, H2 2017

Sepsis – Pipeline by Biomedica Management Corp, H2 2017

Sepsis – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Sepsis – Pipeline by Bristol-Myers Squibb Company, H2 2017

Sepsis – Pipeline by Cell2B Advanced Therapeutics SA, H2 2017

Sepsis – Pipeline by Chiome Bioscience Inc, H2 2017

Sepsis – Pipeline by Cilian AG, H2 2017

Sepsis – Pipeline by Commence Bio Inc, H2 2017

Sepsis – Pipeline by DoNatur GmbH, H2 2017

Sepsis – Pipeline by Dr. Franz Kohler Chemie GmbH, H2 2017

Sepsis – Pipeline by Endacea Inc, H2 2017

Sepsis – Pipeline by Evec Inc, H2 2017

Sepsis – Pipeline by Ferring International Center SA, H2 2017

Sepsis – Pipeline by Huons Co Ltd, H2 2017

Sepsis – Pipeline by Immune Response BioPharma Inc, H2 2017

Sepsis – Pipeline by Immunwork Inc, H2 2017

Sepsis – Pipeline by InflaRx GmbH, H2 2017

Sepsis – Pipeline by Integrated BioTherapeutics Inc, H2 2017

Sepsis – Pipeline by Lead Discovery Center GmbH, H2 2017

Sepsis – Pipeline by Leading BioSciences Inc, H2 2017

Sepsis – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017

Sepsis – Pipeline by Merck & Co Inc, H2 2017

Sepsis – Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017

Sepsis – Pipeline by Navigen Inc, H2 2017

Sepsis – Pipeline by Nohla Therapeutics Inc, H2 2017

Sepsis – Pipeline by Novartis AG, H2 2017

Sepsis – Pipeline by Octapharma AG, H2 2017

Sepsis – Pipeline by OncoImmune Inc, H2 2017

Sepsis – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Sepsis – Pipeline by Opsona Therapeutics Ltd, H2 2017

Sepsis – Pipeline by Peptinov SAS, H2 2017

Sepsis – Pipeline by ProThera Biologics Inc, H2 2017

Sepsis – Pipeline by Ra Pharmaceuticals Inc, H2 2017

Sepsis – Pipeline by Recce Ltd, H2 2017

Sepsis – Pipeline by Ribomic Inc, H2 2017

Sepsis – Pipeline by SciClone Pharmaceuticals Inc, H2 2017

Sepsis – Pipeline by SetLance srl, H2 2017

Sepsis – Pipeline by Shionogi & Co Ltd, H2 2017

Sepsis – Pipeline by Sirtex Medical Ltd, H2 2017

Sepsis – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017

Sepsis – Pipeline by Spider Biotech, H2 2017

Sepsis – Pipeline by Syntiron LLC, H2 2017

Sepsis – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Sepsis – Pipeline by Therakind Ltd, H2 2017

Sepsis – Pipeline by Therashock LLC, H2 2017

Sepsis – Pipeline by TiGenix NV, H2 2017

Sepsis – Pipeline by Vascular BioSciences, H2 2017

Sepsis – Pipeline by ViiV Healthcare Ltd, H2 2017

Sepsis – Dormant Projects, H2 2017

Sepsis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Sepsis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Sepsis – Dormant Projects, H2 2017 (Contd..3), H2 2017

Sepsis – Dormant Projects, H2 2017 (Contd..4), H2 2017

Sepsis – Discontinued Products, H2 2017

Sepsis – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Sepsis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports